ESMO 2022

Consolidating data from prospective studies

Endocrine response in eBC

Immuntherapy only for low risk patients?

Dose dense is better

Reduction of peripheral neuropathy with taxane therapy

Dose-dense therapy is beneficial for all patients

Roadmap for the adjuvant setting

QoL and longterm toxicity

My highlights of ESMO22

Simple and cheap surgical technique may impact survival in early breast cancer

Dose-dense standard of care is the optimal care

DD is the champion!

Hand cooling and compression both effective in preventing chemotherapy-induced peripheral neuropathy

Long-term data on dose density therapy in chemotherapy

Il vincitore e’ il dose dense!!

Datele trialurilor se consolideata

I miei punti salienti di ESMO22

Chłodzenie rąk i terapia kompresyjna skutecznie obniżają ryzyko neuropatii obwodowej po leczeniu taksanami

Schéma dose-dense bénéfique pour toutes les patientes

Rosta i tania technika chirurgiczna może wpływać na czas przeżycia we wczesnym raku piersi

Tailoring Adjuvant Therapy

How to deal with the negative SERD data?

Unmeet needs and my wishes for 2022!

Status update - adjuvant IO. Are TILs prognostic?

Dose-dense CT Efficacy confirmed in the Nodal+ ER+ population. Do all luminal patients benefit? What about secondary malignancies?

DATA: Still open questions on the optimal duration of extended adjuvant endocrine therapy? Greatest effect in the endocrine sensitive population. N+ higher risk. Contralateral disease with longer benefit

Who needs Chemo? Who does not? Is OFS plus endocrine Therapy sufficient without prior Chemo? Response Assessment before surgery

Exciting data, but Phase 3 studies are needed

Negative and yet positive?!

Update on biomarkers on ADCs of the DAISY trial

OS not significant, but re-assuring new data

New treatment option for heavily pre-treated patients with ER+ MBC

The third in the bunch

HER2+ and still without chemotherapy

More therapy options for patients with HR+, HER2+ disease

Endocrine-based therapy may prove more effective than chemo in “triple-positive” advanced breast cancer

Interim analysis shows promising data on Abema in the 1st Line

New data re-inforces SG as a new option pre-treated HR+/HER2- patients

Survival benefit in endocrine sensitive patients

My highlights of ESMO22

Sacituzumab govitecan for everybody!

ADC after ADC - is there any orientation?

CDK4/6i could be an option for selected ER+/HER2+ disease

Discontinued development

VEX has no place in chemotherapy of metastatic breast cancer

TROPiCS-02 highlights

SG is a novel treatment option for HR+/HER2- disease

Survival benefit from SG in mBC

Another option for heavily pre-treated HR+ advanced breast cancer patients

Sopravvivenza globale nello studio MONARCH3

SG come nuova opzione di cura Per pazienti con tumore mammario HR+/HER2-

I miei punti salienti di ESMO22

TROPiCS-02 highlights

Nuove opzioni di trattamento personalizzate per pazienti con tumore mammarioHR+/HER2+

Survie globale pas encore significative statistiquement mais données rassurantes

Nouvelle option thérapeutique pour les patientes lourdement prétraitées RH+ HER2-

Leczenie zaawansowanych raków „potrójnie dodatnich” oparte na hormonoterapii może okazać się bardziej skuteczne niż chemioterapia

Sacituzumab Govitecan: Un farmaco per tutte?

Nouvelles données des analyses expolratoires dans l’étude DAISY

Interim OS Data & PFS Update for Abemaciclib hint towards final consistent OS benefit. We need to focus on resistance drivers.

CDK4/6i plus Trastuzumab – a possible chemo-free option for triple positive patients?

SERDs: equal PFS benefit vs. endocrine therapy; adjuvant data to be expected

Monarch-3: strong OS Survival; DAWNA-2: PFS in line with existing CDK4/6i; monarcHER: a chemo-free treatment option

ADC efficacy in perspective: SG overall survival benefit, efficacy comparable for HER2- and HER2low. ADC sequencing could become an option. We need data for earlier settings.

SG confirms benefit in OS, PFS, ORR, QoL, the new 2nd line Standard of Care? What will be the treatment sequence? A European, US and Asian Perspective

ADAURA Update - preventing relapse or just delaying it?

Pollution and lung cancer - one mechanism revealed

ADAURA revisited

Concurrent preoperative IO/CRT in early lung cancer

Neoadjuvant strategies for PD-L1 < 1 %

Long term follow-up of ADAURA trial

Window for treatment selection

Double IO + chemoradiotherapy - is it feasible in borderline resectable stage III NSCLC patients?

Osimertinib stays standard adjuvant

INCREASE - to good to be true?

Is OS really needed?

Osimertinib - curing or delaying relapse?

Liquid biopsy monitoring of EGFR-mutant lung cancer patients before and after surgery

Dubbele immunotherapie plus chemoradiotherapie - is het haalbaar bij patiënten met borderline resectable stadium III NSCLC?

Osimertinib: una cura o ritarda la ripresa di malattia?

Liquid biopsie monitoring van patiënten met een EGFR mutatie voor en na chirurgie

ADAURA revisited

Eine Plattform für "take the winner"-Strategie

Langzeitdaten ADAURA

Pollution et cancer du poumon - un mécanisme mis en évidence

Osimertinib bleibt Standard adjuvant

DFS matters!

Important data on borderline resectable patients

Sotorasib vs. Docetaxel in mKRAS G12C

Long term follow-up of KEYNOTE-189 and KEYNOTE-407

Can IO be discontinued?

Sotorasib - a new standard of care?

Question about timing and duration of immunotherapy still unanswered

Emerging IO mono options in the first line

5-year update on 1st line chemoimmunotherapy

The journey at KRAS G12C continues

New immunotherapy options for pts. ineligible to 1st line platinum therapy

5 years of chemoimmunotherapy: solid grounded

Is shorter immunotherapy equally effective and less physically demanding?

Poseidon and STK11/KEAP

Preview on lung cancer highlights

Induction chemoimmunotherapy in borderline resectability?

Immunotherapy in unfit population? Perhaps...

DESTINY-Lung02 - better than the original?

Atezolizumab better than vinorelbin in reduced performance status

Pneumonitis and T-DXd

New therapy combination after progression on 1L osimertinib

Cemiplimab beyond progression?

A new step in treatment of KRAS G12C mutant NSCLC

HER2 - the next actionable mutation in lung cancer?

Chemoimmunotherapy - improvement of survival after 5 years

Duration of immunotherapy : Stop and go strategy for Nivo/Ipi

Can we finally treat poor prognostic patients with immunotherapy?

Real-world data on Atezolizumab

One more brick in the KRAS G12C wall

Liquid biopsy monitoring in treatment decisions

If you don't look, vou don't find - once you found it, you'll treat it!

Sotorasib: sweet and sour results

5-year data on survival under immunotherapy

Chimio-immunothérapie - amélioration de la survie après 5 ans

Kunnen we eindelijk patiënten met een slechte prognose behandelen met immunotherapie?

IO-IO neoadjuvant bei PD-L1 neg.

Immunoterapia nella popolazione non fit: forse

Kann IO pausiert werden?

Se non lo cerchi non lo troiv. Quando lo hai trovato, trattalo

Chemo-IO-Induktion bei grenzwertiger Resektabilität?

5 Jahre Chemo-Immuntherapie: starker Effekt

Sotorasib vs. Docetaxel bei mKRAS G12C

Neue Therapiekombination in der Resistenz nach Osimertinib

Pneumonitis und T-DXd

Un mattone in piu' nel muro del KRAS G12C

5-Jahresüberleben mit Immuntherapie

Liquid Biopsy Monitoring zur Therapiesteuerung

Cemiplimab beyond progression?

Kürzere Immuntherapie gleich effektiv aber weniger belastend?

Una nueva opción de tratamiento con IO en pacientes no tributarios de 1L con platino

Une nouvelle étape dans le traitement du CBNPC KRAS G12C muté

Neue Option der IO-Therapie in der Erstlinie

Die Reise bei KRAS G12C geht weiter

Resultados Agridulces de Sotorasib

Durée de l'immunothérapie : stratégie Stop and Go pour l 'association Nivo/Ipi

Atezo besser als Vino bei PS2-3

Données de vie réelle avec l’atezolizumab

Poseidon und STK11/KEAP

Les études incontournables à l’ESMO 2022

A positive study! With a question mark?

Novel data and long-term efficacy of chemo-IO in mNSCLC

Heterogenity in the genetic landscape - little progress in molecular alterations

New strategies in immunotherapy

Adjuvant Immuntherapy in kidney cancer

More questions being raised

Exciting data for high-risk patients: is this the start of a new era?

Immune-based peri-operative treatment in RCC: What went wrong?

No value of IPI/Nivo in the adjuvant setting.

Brief highlights about RCC & urothelial cancer from ESMO22

Place of triplet therapy

Adjuvant CPI in kidney cancer – 2 phase III trials with novel insights!

News in terms of adjuvant

New combo - triplet therapy for kidney cancer

Two negative studies question adjuvant approach in RCC

Inmunoterapia adyuvante en el cancer renales

Μηνύματα από το ESMO22 για τον καρκίνο του νεφρού

Terapia triple para cancer renales

Tratamiento perioperatorio con immunoterapia en cáncer renal: Que ha fallado?

Shedding light on TKI/Checkpointinhibitor combinations

Therapy combinations in RCC - what is the role of triplet therapy?

Adjuvant immunotherapy options in RCC - what do we learn from ESMO22 data for the adjuvant setting?

Immunomodulation in combination with checkpointinhibiton

EV + pembrolizumab in cisplatin-ineligible patients

EV + Pembro with excellent response rates

Brief highlights about RCC & urothelial cancer from ESMO22

Μηνύματα από το ESMO22 για τον ουροθηλιακό καρκίνο

Biomarker exploration in urothelial cancer - finding the right assay for the right drug!

Adjuvant and neoadjuvant therapy approaches in urothelial cancer

Promising data, but beware of toxicity

Update on the PROpel study

ADCs - a possible therapeutic approach

PSA at 8-months as a biomarker

Radicals - ADT & Radiotherapy

Biomarker data for better patients selection

Combination of olaparib leads to promising results

IO + PARP without benefit in the allcomer situation

Length of hormone therapy after radiation

Genetic testing before PARP therapy is useful

ADT + ENZA better choice than monotherapy

Cabazitaxel better tolerated in elderly men

QoL data from ARASENS triplet therapy study mHRPC

Triplet therapy with darolutamide in prostate cancer

Optimizing cabazitaxel chemotherapy

In older vulnerable - less is more

Further evaluation of PSA correlates

IM arbiraterone decanoate might demonstrate superior therapeutic index and tolerability

Should intensification of ADT be considered in high-risk biochemically relapsed PC?

Uppdatering i PROpel studien

PSA efter 8 månader i PEACE-1 studien som biomarkör

Livskvalitetsuppföljning i ARASENS studien

Intimate partner violence in cancer patients

IAP-inhibition – comming game changer in LA-HNSCC Radiochemotherapy

TILs - Fashion is the eternal return of the old

Addition of CPI to Radiochemotherapy in LA-HNSCC?

Novel approach von Biontech towards Cancer – game changing potential?!

New group of substances for rare diseases